Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT

IntroductionSince allogeneic stem cell transplantation (allo-HSCT) is considered one of the curative treatments for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), hematological relapse following allo-HSCT remained a crucial concern for patients’ survival. MethodsWe retrospectively...

Full description

Bibliographic Details
Main Authors: Zhangjie Chen, Sisi Zhen, Tingting Zhang, Yuyan Shen, Aiming Pang, Donglin Yang, Rongli Zhang, Qiaoling Ma, Yi He, Jialin Wei, Weihua Zhai, Xin Chen, Erlie Jiang, Mingzhe Han, Sizhou Feng
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
venetoclax
myeloid malignancy
acute myeloid leukemia
allo-HSCT
relapse
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1137175/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1137175/full

Similar Items